American Biogenetic Sciences presents Solfib data at Society of Thrombosis and Haemostasis (STH):
This article was originally published in Clinica
Executive Summary
American Biogenetic Sciences' says Solfib its soluble fibrinogen assay is an excellent rule-out test for MI and can identify patients at risk of post-operative thrombosis. The soluble fibrinogen antibody could also be used to deliver thrombolytics, according to data presented at the International Society of Thrombosis and Haemostasis' annual congress (Jerusalem, June 11th-16th). The negative predictive value for MI is 100%, according to data presented by ABS president Dr Paul Gargan. He described the MI rule-out finding highly significant - because of the potential cost savings. Only 15% of patients who are assessed for chest pain actually have MI.
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.